Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Solara announces Q2FY20 Financial Results

Posted On: 2019-10-22 21:55:11


Solara Active Pharma Sciences Ltd (Solara) (NSE: SOLARA; BSE: 541540), a leading Active Pharmaceutical Ingredient provider today announced the financial results for the second quarter (Q2FY20).

- Revenues at Rs. 3,561 Mn up by 4% YoY, EBITDA up 43% YoY at Rs. 705 Mn
- Continued momentum resulting in >20% operating margins for four quarters in a row
- 2x growth in PAT to Rs. 289 Mn in Q2FY20
- Reported highest ever EPS in a quarter at Rs. 11.21
- Momentum across the cost improvement programs and a favourable product mix resulted into 350 basis point improvement in the Operating EBITDA margins over the same period in the previous year.

- Reported forex loss of Rs. 3mn in Q2FY20 as against the loss of Rs. 64mn in Q2FY19.
- Our Reported EBITDA margins in Q2FY20 are at 19.8%, which is a 540 basis point expansion over the same period in the previous year

- Top ten customers and ten products account for 51% and 79% of revenues respectively in Q2FY20.

Jitesh Devendra, MD and CEO commented "We are happy to report yet another quarter of consistent performance thereby delivering profitable growth. While we had a 4% growth in the revenues, our EBITDA grew by over 43% resulting in a fourth successive quarter of >20% Operating margins. This performance also led to a two times growth in the PAT, which is now at Rs. 289Mn.

From a business standpoint, our combined growth of base business and new products continue to perform on the expected lines and receive traction from the new customers and existing partners alike. We sustained our focus on R&D and filed one additional drug master file for the US markets and did market extensions for three of our existing products to four new markets. With our basket of commercialised APIs and R&D pipeline, We are reasonably placed for the growing industry opportunities. On the CRAMS front, we have had a series of positive customer interactions and progression in the funnel build-out, thereby indicative of a promising future. The CRAMS business is still in incubation, and with our relentless efforts, we are hopeful of achieving a commercial breakthrough in the near term.

During the quarter, one of our top 10 products Ranitidine Hydrochloride experienced regulatory headwinds due to USFDA's notification around the NDMA impurity in the product, and we had voluntarily suspended our sales and production of the product. While the USFDA has suggested all the drug substance manufacturers to conduct some specific tests on this issue, it did not notify any product recalls for the Ranitidine formulations. We have completed our internal assessment on the criteria indicated and are now collaborating with the agency and our customers to understand the next set of actions. We firmly believe that the issue is temporary and should not impact the prospects of our performance this fiscal. We continue to remain optimistic about meeting our growth outlook."

Shares of Solara Active Pharma Sciences Ltd was last trading in BSE at Rs.418.05 as compared to the previous close of Rs. 409.45. The total number of shares traded during the day was 10572 in over 820 trades.

The stock hit an intraday high of Rs. 448.65 and intraday low of 408.1. The net turnover during the day was Rs. 4573586.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Multi Commodity Exchange of India Ltd Board approves dividend of Rs. 30

The Great Eastern Shipping Company Ltd reports loss of Rs. 50.68 crore in Q4 FY20

CreditAccess Grameen Ltd Q4 FY20 consolidated PAT slips to Rs. 28.84 crore

Amber Enterprises India Ltd Q4 consolidated PAT at Rs. 62.84 crore

Mercury Laboratories Ltd Q4 loss at Rs. 0.35 crore

Moody's downgrades India Infoline Finance Limited to B1 from Ba3, ratings remain under review for downgrade

Mercury Laboratories Ltd Board recommends Dividend of Rs. 2 for FY20

MCX Q4 consolidated net profit up at Rs. 65.50 crore

Lemon Tree Hotels Ltd board approves fund raising proposal

Amara Raja Batteries Ltd reports Q4 FY20 consolidated net profit of Rs. 137.30 crore

Seshasayee Paper and Boards Ltd board recommends dividend of Rs. 4

IDBI Bank Back in Black, registers Net Profit of Rs. 135 crore in Q4 FY 2020 after 13 Quarters

Polycab India Ltd reports Rs. 213.93 crore consolidated PAT in Q4 FY20

KEI Industries Ltd posts consolidated PAT of Rs. 62.03 crore in Q4 FY20

Seshasayee Paper and Boards Ltd Q4 FY20 consolidated PAT at Rs. 48.01 crore

The Great Eastern Shipping Company Ltd board declares interim dividend of Rs. 2.70

Kotak Mahindra Bank allots 6.5 crore shares at Rs. 1145 per share

Affle India Ltd Q4 consolidated PAT up YoY at Rs. 15.28 crore

Advanced Enzyme Technologies Ltd board recommends dividend of Rs. 0.60

RCF's Q4 2019-20 profit after tax rises over 190 % over Q4 2018-19

Eris Lifesciences Ltd board to consider Q4, FY20 results on June 2, 2020

Advanced Enzyme Technologies Ltd Q4 consolidated PAT at Rs. 31.33 crore

Kaveri Seed Company Ltd Q4 FY20 consolidated net profit at Rs. 7.57 crore

Kanpur Plastipack Ltd Board recommends final dividend of Rs. 0.60 for FY20

Techno Electric & Engineering Company Ltd to sell its stake in JKTPL

NLC India Limited raises Rs. 500 crore through Commercial Paper

Kanpur Plastipack Ltd Q4 PAT at Rs. 0.47 crore

CRISIL updates on rating of Jubilant Life Sciences Limited

KRBL Limited board to announce Q4, FY20 results on June 9, 2020

Sagar Cements Ltd reports Rs. 1.29 crore consolidated PAT in Q4 FY20

Procter & Gamble Health Ltd posts Rs. 46.46 crore PAT during the quarter ended March 31, 2020

Customer Service a Priority: Maruti Suzuki announces extension of free service and warranty

Suven Life Sciences Ltd board to consider Q4, FY20 results on June 5, 2020

Everest Industries Ltd Board recommends dividend of Rs. 1 for FY20

ESAF Small Finance Bank Profit Soars 110%

Lemon Tree Hotels Ltd Q4 FY20 loss at Rs. 17.91 crore

IndiGo announces the appointment of Dr. Venkataramani Sumantran as an Independent Director

Sundaram Finance FY20 Net Profit at Rs. 724 crores, revenues up 16% at Rs. 3842 crores

KPTL announces execution of share purchase agreement for divestment of stake in Jhajjar KT Transco Transmission Asset

YES Bank acquires 24.19% in Dish TV India Ltd through invocation of pledged shares

V-Mart reports 16% revenue growth and 61% increase in EBITDA y-o-y in FY20

India Ratings Maintains Union Bank of India on RWE

CRISIL assigns 'CRISIL AAA/Stable' Rating on Rs. 500 crores NonConvertible Debenture (NCD) Programme of M&M

SCI Q4 consolidated PAT at Rs. 111.05 crore

IndiGrid announces execution of share purchase agreement for acquisition of Jhajjar KT Transco Private Limited

The Shipping Corporation of India Limited board recommends final dividend of Rs. 0.75

Sundaram Finance Ltd Board recommends Final Dividend of Rs. 3

Equitas Holdings Ltd Q4 consolidated PAT slides to Rs. 14.59 crore

Metropolis Healthcare Ltd Q4 consolidated PAT drops to Rs. 15.49 crore

VOLTAS Ltd Q4 consolidated PAT up at Rs. 158.66 crore







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019